Zantac, generics ordered off the market after FDA finds they're a ticking time bomb

Nearly four decades after it was approved, the FDA has ordered that heartburn drug Zantac and its generics be removed from the market, saying they have been exposing consumers to the risk of cancer.

The move comes six months after an independent lab warned the FDA of a potential carcinogen in ranitidine drugs and nearly three months after another lab told the FDA its tests determined levels of NDMA could increase if the drug is stored above room temperature.